Skip to main content
SpringerLink
Log in

A Multicenter Phase II Study of Docetaxel 60 mg/m2 as First-Line Chemotherapy in Patients with Advanced or Recurrent Breast Cancer

  • Original Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Purpose

Docetaxel is an active agent as first-line chemotherapy in patients with advanced breast cancer at a dosage of 100 mg/m2. However, the efficacy of this agent as a first-line drug when used at a lower dosage is unclear. This study was performed to evaluate the clinical efficacy and safety of 60 mg/m2 docetaxel for the treatment of breast cancer.

Patients and Methods

This study enrolled 23 patients with advanced and/or metastatic breast cancer, who had not been treated with an anthracycline or taxane previously. Treatment with docetaxel was continued in patients showing a response until there was evidence of disease progression or unacceptable toxicity.

Results

Among 20 fully evaluated patients, the overall response rate was 50.0% and the median time to progression was 31 weeks. The most commonly observed adverse events were neutropenia (78.2%) and fatigue (60.9%). Fluid retention occurred in only 8.7% of the patients. Adverse events did not cause discontinuation of the treatment.

Conclusion

Docetaxel achieved good disease control with mild adverse events in first-line treatment at a dosage of 60 mg/m2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aapro MS: Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.Semin Oncol 26:17–21, 1999.

    PubMed  CAS  Google Scholar 

  2. A’Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type schedules.Br J Cancer 67:801–805, 1993.

    PubMed  CAS  Google Scholar 

  3. Early Breast Cancer Trialists’ Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomised trials.Lancet 352:930–942, 1998.

    Article  Google Scholar 

  4. Crown J: A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.Semin Oncol 26:5–9, 1999.

    PubMed  CAS  Google Scholar 

  5. Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracyclineresistant or anthracenedione-resistant breast cancer.J Clin Oncol 13:2879–2885, 1995.

    PubMed  CAS  Google Scholar 

  6. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.J Clin Oncol 13:2886–2894, 1995.

    PubMed  CAS  Google Scholar 

  7. Sjostrom J, Mourisden H, Pluzanska A, Ottosson L, Bengtsson N-O, Ostenstad B: Taxotere (T) versus methotrexate-5-fluorouracil (MF) in patients with advanced anthracycline-resistant breast cancer: preliminary results of a randomized phase III study by Scandinavian Breast Cancer Group.Proc Am Soc Clin Oncol 17:111a (abtstr. 427), 1998.

    Google Scholar 

  8. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S: Docetaxel vs 5- fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure.Br J Cancer 18:1210–1215, 2002.

    Article  Google Scholar 

  9. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, T. A. Vandenberg, B. Rapoport, R. Rosso, V. Trillet-Lenoir, J. Drbal, A. Molino, J.W.R. Nortier, D. J. Richel, T. Nagykalnai, P. Siedlecki, N. Wilking, J. Y. Genot, P.S.G.J. Hupperets, F. Pannuti, D. Skarlos, E. M. Tomiak, M. Murawsky, M. Alakl, A. Riva, M. Aapro, 304 Study Group. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.J Clin Oncol 17:1413–1424, 1999.

    PubMed  CAS  Google Scholar 

  10. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E. Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group.J Clin Oncol 8:2341–2354, 1999.

    Google Scholar 

  11. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.J Clin Oncol 13:314–322, 1995.

    PubMed  CAS  Google Scholar 

  12. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A, Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as firstline treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC.Ann Oncol 7:165–171, 1996.

    PubMed  CAS  Google Scholar 

  13. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L: Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.J Clin Oncol 14:58–65, 1996.

    PubMed  CAS  Google Scholar 

  14. Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM: Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol 14:422–428, 1996.

    PubMed  CAS  Google Scholar 

  15. Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P: A multicentre phase II study of docetaxel 75 mg/m2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.Br J Cancer 74:650–656, 1996.

    PubMed  CAS  Google Scholar 

  16. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubicin as first-line singleagent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over.J Clin Oncol 4:724–733, 2000.

    Google Scholar 

  17. Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H, Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.Br J Cancer 73:210- 216, 1996.

    PubMed  CAS  Google Scholar 

  18. Ando M, Watanabe T, Nagata K, Narabayashi M, Adachi I, Katsumata N: Efficacy of docetaxel 60 mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.J Clin Oncol 19:336–342, 2001.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, Yokohama City University Medical Center, 4-57, Urafunecho, 232-0024, Minami-ku, Yokohama, Japan

    Takashi Ishikawa

  2. Department of Surgery, Yokohama Minami Kyosai Hospital, Japan

    Satoru Shimizu

  3. Department of Surgery, Breast and Thyroid Division, Kanagawa Cancer Center, Japan

    Masaaki Inaba & Taro Asaga

  4. Department of Surgery, Hiratsuka Kyosai Hospital, Japan

    Kiyohumi Katayama

  5. Department of Surgery, St. Marianna University School of Medicine, Japan

    Mamoru Fukuda

  6. Department of Surgery, School of Medicine, Tokai University, Japan

    Yutaka Tokuda & Kazuo Ishida

  7. Department of Breast Surgery, Kameda Medical Center, Japan

    Eisuke Fukuma

  8. Department of Surgery, Saiseikai Yokohama City Nanbu Hospital, Japan

    Takashi Suda

  9. Department of Surgery, Yokosuka Kyosai Hospital, Japan

    Yohei Hamaguchi

  10. Department of Surgery, Yokohama Municipal Citizen’s Hospital, Japan

    Akira Ishiyama

  11. Department of Gastroenterological Surgery, Yokohama City University, Graduate School of Medicine, Japan

    Hiroshi Shimada

Authors
  1. Takashi Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Satoru Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masaaki Inaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Taro Asaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kiyohumi Katayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mamoru Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yutaka Tokuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuo Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eisuke Fukuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Takashi Suda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yohei Hamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Akira Ishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hiroshi Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Kanagawa Breast Cancer Treatment Society (KBCTS)

Corresponding author

Correspondence to Takashi Ishikawa.

About this article

Cite this article

Ishikawa, T., Shimizu, S., Inaba, M. et al. A Multicenter Phase II Study of Docetaxel 60 mg/m2 as First-Line Chemotherapy in Patients with Advanced or Recurrent Breast Cancer. Breast Cancer 11, 374–379 (2004). https://doi.org/10.1007/BF02968045

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02968045

Key words

Search

Navigation